No Data
Heron Therapeutics Initiated at Buy by Rodman & Renshaw
Heron Therapeutics Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On Heron Therapeutics With Buy Rating, Announces Price Target of $7
Heron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/13/2024 89.19% Rodman & Renshaw → $7 Initiates Coverage On → Buy 05/16/2024 35.14% Needham $5 → $5 Reit
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Rodman & Renshaw Initiates Heron Therapeutics(HRTX.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Heron Therapeutics(HRTX.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
TrytosaveabitOP : Before EOY ((((. Heron Anticipates FDA Action on Zynrelef Within 4-6 Months ))))